This is attributed to elevated miR‐191 in intrahepatic cholangiocarcinoma, which reduces the expression of TET1, leading to a decrease in the anticancer activity of p53, which ultimately promotes the development of intrahepatic cholangiocarcinoma [327]. The gene discussed is TP53; the disease is intrahepatic cholangiocarcinoma.